Pharmacokinetics and amyloid plaque targeting ability of a novel peptide-based magnetic resonance contrast agent in wild-type and Alzheimer's disease transgenic mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 322, Issue 2, 2007, Pages 541-549

  Kandimalla, Karunya K ^a,b   Wengenack, Thomas M ^a   Curran, Geoffry L ^a   Gilles, Emily J ^a   Poduslo, Joseph F ^a,c  

^a MAYO GRADUATE SCHOOL   (United States)

^b FLORIDA A AND M UNIVERSITY   (United States)

^c Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; GADOLINIUM; GADOLINIUM AMYLOID BETA PROTEIN I 125; IODINE 125; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BLOOD BRAIN BARRIER; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG ELIMINATION; IMAGE QUALITY; IMAGE RECONSTRUCTION; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIOIODINATION; SIGNAL DETECTION; TRANSGENIC MOUSE; WILD TYPE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BRAIN; CEREBRAL CORTEX; CONTRAST MEDIA; GADOLINIUM; HIPPOCAMPUS; HUMANS; KINETICS; MAGNETIC RESONANCE IMAGING; MICE; MICE, INBRED STRAINS; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; PRESENILIN-1; SENILE PLAQUES;

EID: 34547135442     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.119883     Document Type: Article

References (18)

1. Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, Welch D, Manness L, Lin C, Yu J, et al. (2003) RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 9:907-913.
2. Deane R, Wu Z, Sagare A, Davis J, Du Yan S, Hamm K, Xu F, Parisi M, LaRue B, Hu HW, et al. (2004) LRP/amyloid β-peptide interaction mediates differential brain efflux of Aβ isoforms. Neuron 43:333-344.
3. Giles KE, Kandimalla KK, Ramirez-Alvarado M, and Poduslo JF (2005) Development of A beta 40 derivatives that do not form fibrils as MRI contrast agents for detecting Alzheimer's disease amyloid plaques. J Neurochem 94:27.
4. Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, Jantzen P, Wright K, Saad I, Mueller R, Morgan D, et al. (1998) Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med 4:97-100.
5. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang FS, and Cole G (1996) Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 274:99-102.
6. 125I-amyloid β protein 40 in wild-type and Alzheimer's disease transgenic mice (APP, PS1) and its implications for amyloid plaque formation. J Pharmacol Exp Ther 313:1370-1378.
7. Kandimalla KK, Curran GL, Holasek SS, Gilles EJ, Wengenack TM, Ramirez-Alvarado M, and Poduslo JF (2006) Physiological and biophysical factors that influence Alzheimer's disease amyloid plaque targeting of native and putrescine modified human amyloid β40. J Pharmacol Exp Ther 318:17-25.
8. Klunk WE, Engler H, Nordberg A, Bacskai BJ, Wang Y, Price JC, Bergstrom M, Hyman BT, Langstrom B, and Mathis CA (2003) Imaging the pathology of Alzheimer's disease: amyloid-imaging with positron emission tomography. Neuroimaging Clin North Am 13:781-789.
9. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergstrom M, Savitcheva I, Huang GF, Estrada S, et al. (2004) Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55:306-319.
10. Lee HJ, Zhang Y, Zhu C, Duff K, and Pardridge WM (2002) Imaging brain amyloid of Alzheimer disease in vivo in transgenic mice with an Aβ peptide radiopharmaceutical. J Cereb Blood Flow Metab 22:223-231.
11. Poduslo JF and Curran GL (1996) Increased permeability of superoxide dismutase at the blood-nerve and blood-brain barriers with retained enzymatic activity after covalent modification with the naturally occurring polyamine, putrescine. J Neurochem 67:734-741.
12. Poduslo JF, Curran GL, Peterson JA, McCormick DJ, Fauq AH, Khan MA, and Wengenack TM (2004) Design and chemical synthesis of a magnetic resonance contrast agent with enhanced in vitro binding, high blood-brain barrier permeability, and in vivo targeting to Alzheimer's disease amyloid plaques. Biochemistry 43:6064-6075.
13. Poduslo JF, Curran GL, Sanyal B, and Selkoe DJ (1999) Receptor-mediated transport of human amyloid β-protein 1-40 and 1-42 at the blood-brain barrier. Neurobiol Dis 6:190-199.
14. Poduslo JF, Wengenack TM, Curran GL, Wisniewski T, Sigurdsson EM, Macura SI, Borowski BJ and Jack CR Jr (2002) Molecular targeting of Alzheimer's amyloid plaques for contrast-enhanced magnetic resonance imaging. Neurobiol Dis 11: 315-329.
15. Selkoe DJ (2001) Clearing the brain's amyloid cobwebs. Neuron 32:177-180.
16. Wadghiri YZ, Sigurdsson EM, Sadowski M, Elliott JI, Li Y, Scholtzova H, Tang CY, Aguinaldo G, Pappolla M, Duff K, et al. (2003) Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance microimaging. Magn Reson Med 50: 293-302.
17. Wengenack TM, Curran GL, and Poduslo JF (2000a) Targeting Alzheimer amyloid plaques in vivo. Nat Biotechnol 18:868-872.
18. Wengenack TM, Whelan S, Curran GL, Duff KE, and Poduslo JF (2000b) Quantitative histological analysis of amyloid deposition in Alzheimer's double transgenic mouse brain. Neuroscience 101:939-944.